Life Science Investing ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting 07 December
Life Science Investing ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update 07 November
